UNSPSC 51201572: Vedolizumab

An integrin receptor antagonist.

UNSPSC 51201572 Vedolizumab is a Commodity code that nominally classifies a specific biologic pharmaceutical agent for inflammatory bowel disease treatment. However, the recent state and local contract opportunities posted under this code show no procurement activity aligned with vedolizumab or related pharmaceutical products. Instead, the opportunities tagged to this code describe athletic training services for municipal public-safety personnel, general medical aid supplies for fire rescue departments, and a state-level request for information regarding direct-to-manufacturer prescription programs. The mismatch between the code's nominal scope and the actual solicitations suggests either systematic tagging errors in the state and local procurement systems or that this code is not capturing genuine pharmaceutical procurement activity at the state and local level.

The three most recent opportunities posted under this code originate from the City of Tucson (athletic training RFP, May 2026, due June 9, 2026), the City of Tampa Fire Rescue Department (medical aid supplies ITB, April 2026), and the Texas Health and Human Services Commission (RFI on direct-to-manufacturer prescriptions, April 2026). These solicitations span Arizona, Florida, and Texas but represent disparate service and product categories unrelated to vedolizumab procurement. No issuing bodies show repeat activity under this code, and no dollar values, vendor names, or contract awards are disclosed for vedolizumab itself. This code appears to see minimal or misdirected recent activity and warrants verification against actual procurement intent before deploying business development resources.